Focused On-demand Library for DDB1- and CUL4-associated factor 15

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q66K64

UPID:

DCA15_HUMAN

Alternative names:

Alternative UPACC:

Q66K64; B3KS86; Q96DW0; Q9BU31

Background:

DDB1- and CUL4-associated factor 15 (DCAF15) plays a pivotal role in cellular processes as a substrate-recognition component of the DCX complex. This complex, a cullin-4-RING E3 ubiquitin-protein ligase, is crucial for the ubiquitination and degradation of target proteins. DCAF15 is instrumental in regulating the effector functions of natural killer (NK) cells, potentially through the ubiquitination and degradation of cohesin subunits SMC1A and SMC3. It may also enhance the activation of antigen-presenting cells (APC) and their interaction with NK cells.

Therapeutic significance:

Understanding the role of DDB1- and CUL4-associated factor 15 could open doors to potential therapeutic strategies. Its interaction with aryl sulfonamide anticancer drugs, which alter the substrate specificity of the DCX(DCAF15) complex, underscores its therapeutic significance. These drugs promote the degradation of splicing factors like RBM39, leading to splicing defects and cancer cell death, highlighting DCAF15's potential in cancer therapy.